Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 12/20 | 0.39 |
| ▸ | VDR | P11473 | 5/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | GLP1R | P43220 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5523208 | 0.99 | L3MBTL1 (0.39) | L3MBTL1NR1H4VDRRORCCYP2C9 | |
| SCHEMBL5508831 | 0.99 | L3MBTL1 (0.41) | L3MBTL1NR1H4VDRRORCCYP2C9 | |
| Hydrochloric Acid SCHEMBL5513175 | 0.98 | L3MBTL1 (0.40) | L3MBTL1NR1H4VDRRORCCYP2C9 | |
| SCHEMBL13285953 | 0.94 | L3MBTL1 (0.40) | L3MBTL1NR1H4VDRRORCPTGER1 | |
| SCHEMBL14383828 | 0.94 | RORC (0.37) | L3MBTL1NR1H4VDRRORCCYP2C9 | |
| Hydrochloric Acid SCHEMBL5512974 | 0.93 | RORC (0.37) | L3MBTL1NR1H4VDRRORCCYP2C9 | |
| SCHEMBL5516852 | 0.92 | RPS6KB1 (0.42) | L3MBTL1NR1H4VDRCYP2C9CYP3A4 | |
| SCHEMBL791571 | 0.90 | L3MBTL1 (0.41) | L3MBTL1NR1H4VDRRORCPTGER1 | |
| Hydrochloric Acid SCHEMBL5514460 | 0.90 | L3MBTL1 (0.41) | L3MBTL1NR1H4VDRRORCPTGER1 | |
| Hydrochloric Acid SCHEMBL5516920 | 0.90 | L3MBTL1 (0.40) | L3MBTL1NR1H4VDRCYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-7285551-B2 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7285551-B2 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | L3MBTL1 4435/4885NR1H4 369/4885VDR 4852/4885 |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | GTF3C5, ZC3HAV1, POLI | L3MBTL1 4165/4885NR1H4 616/4885VDR 4864/4885 |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | GTF3C5, ZC3HAV1, POLI | L3MBTL1 4165/4885NR1H4 616/4885VDR 4864/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | L3MBTL1 4435/4885NR1H4 369/4885VDR 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.